The largest numbers of GLP-1R cells were observed in regions associated with autonomic and behavioural control of energy balance, such as the paraventricular nucleus (PVN), arcuate nucleus (ARC), dorsomedial hypothalamic nucleus (DMH) and central amygdala
The best choice depends on your individual health goals, medical history, and how your body responds to treatment
Note that some people with more insulin resistance will not lose weight until they're on the slightly higher dose in the second or third month
The clinical data on how common menstrual changes are The SURMOUNT-1 and SURMOUNT-2 trials enrolled women of reproductive age but didn't specifically track menstrual cycle changes as a primary endpoint
Pattern 1: The Responder (approximately 60% of switchers) Achieves similar or better weight-loss velocity on Zepbound 7.5 to 10 mg compared to prior Wegovy 2.4 mg Tolerates titration well with transient nausea that resolves within 2 weeks per dose escalation Reaches maintenance dose by week 12 to 16 Reports subjective improvement in appetite suppression ("Zepbound feels stronger") This is the modal response
Serial examinations at regular intervals let us monitor whether retinal changes are stable, improving, or worsening
